146P Phase (ph) Ib results of bemarituzumab (BEMA) added to capecitabine/oxaliplatin (CAPOX) or S-1/oxaliplatin (SOX) with or without nivolumab (NIVO) for previously untreated advanced gastric/gastroesophageal junction cancer (G/GEJC): FORTITUDE-103 study
Year: 2023
Type: article
Source: Annals of Oncology
Authors: K-W. Lee, Y-K. Kang, M-H. Chen, H. Hirano, Y. Sunakawa, S.T. Kim, C-C. Lin, W.P. Yong, T. Kawakami, T. Oshima, Z. Li, M. Hopkins, A. Levin, H. Wang, L. Goldstein, D. Zhou, S.Y. Rha
Institutions: Seoul National University Bundang Hospital, Asan Medical Center, University of Ulsan, Taipei Veterans General Hospital, National Cancer Center Hospital, St. Marianna University School of Medicine, Samsung Medical Center, National Taiwan University Hospital, National University Health System, Shizuoka Cancer Center, Kanagawa Cancer Center, Amgen (United States), Amgen (United Kingdom), Yonsei University, Yonsei University Health System
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: AstraZeneca, Memorial Sloan-Kettering Cancer Center, Clinical Trial Center, China Medical University Hospital, Kindai University, Kanazawa University, University of Ulsan, Khon Kaen University, Universidad de Navarra, Chinese University of Hong Kong, Ludwig-Maximilians-Universität München, Universitat de Barcelona, Humanitas University, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Humanitas Research Hospital, University of California, San Francisco, National Cancer Institute, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco
OpenAlex ID: W4389279812